foxo4-dri senolytic peptide human trials The disordered p53 transactivation domain is the target of FOXO4 and the compound The disordered p53 transactivation domain
Description
Supplied as a stable lyophilised solid for controlled handling

Manufactured By: Schazoo Pharmaceuticals

This cell-permeable peptide antagonist blocks the interaction of FOXO4 and p53.

Sold by the vial 2ml
